In this study, we focused on elucidating the molecular mechanisms contributing to sorafenib resistance, and we present a novel therapeutic approach for the treatment of advanced HCC patients by targeting EphA2. This evidence concerns the gene EPHA2 and hepatocellular carcinoma.